ResearcherParker Institute for Cancer ImmunotherapyActive in the last 2 years
Lacey Padrón
Matched on ORCID iD 0000-0003-0064-5565; OpenAlex author ID A5009517654. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 3
- Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Co-author DOI 10.1136/jitc-2025-012864↗
- Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
- Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Co-author DOI 10.1038/s41591-022-01829-9↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Zev A. Wainberg · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Andrew H. Ko · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Robert A. Wolff · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Eileen Mary O'Reilly · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Robert H. Vonderheide · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- George Albert Fisher · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Mark H. O’Hara · 3 shared papers, 2022–2026 · strength 0.45
- Paper Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydr… DOI 10.1136/jitc-2025-012864↗
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Osama E. Rahma · 2 shared papers, 2022–2024 · strength 0.23
- Paper Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. DOI 10.1038/s41467-024-49915-5↗
- Paper Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic ana… DOI 10.1038/s41591-022-01829-9↗
- Ravi K. Amaravadi · 1 shared paper, 2026 · strength 0.22
- William Arthur Hoos · 1 shared paper, 2026 · strength 0.22
- Alec C. Kimmelman · 1 shared paper, 2026 · strength 0.22
- Neha Bhagwat · 1 shared paper, 2024 · strength 0.13
- Peter James O'Dwyer · 1 shared paper, 2024 · strength 0.13
- Samuele Cannas · 1 shared paper, 2024 · strength 0.13
- Thomas Benjamin Karasic · 1 shared paper, 2024 · strength 0.13
- Jennifer Rachel Eads · 1 shared paper, 2024 · strength 0.13
- Jacob Edward Till · 1 shared paper, 2024 · strength 0.13
- Erica L. Carpenter · 1 shared paper, 2024 · strength 0.13
- Kim A. Reiss · 1 shared paper, 2024 · strength 0.13
- Marco Tognetti · 1 shared paper, 2022 · strength 0.10
- Katelyn T. Byrne · 1 shared paper, 2022 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.